Перейти к основному содержанию

SCIENTIFIC-PRACTICAL PEER-REVIEWED MONTHLY JOURNAL.
INSTITUTION OF MINISTRY OF PUBLIC HEALTH OF THE REPUBLIC OF BELARUS

EFFICACY AND SAFETY OF ATORVASTATIN THERAPY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASES

Objective. The efficacy and safety of generic Atorvastatin in patients with chronic obstructive pulmonary diseases (COPD) and/or asthma combined with hyperlipidemia were evaluated.

Materials and methods. 73 participants receiving standard COPD/asthma treatment were enrolled. The patients were randomly assigned to receive Atorvastatin (produced by “Belmedpreparaty”, Belarus) 20 mg per day for 24 weeks in addition (n=46) or the standard treatment only (n=27).

Results. Generic Atorvastatin in COPD patients was determined to reduce the total cholesterol (TC) by 26% (р=0.005), the low-density lipoprotein cholesterol (LDL-C) by 17% (p=0.26), the triglycerides (TG) by 14% (p=0.047). The adverse events incidence was 11%, the frequency of Atorvastatin discontinuation was 6.5%. The generic Atorvastatin was found to be safe and effective in COPD patients the safety and efficacy profile being similar to the foreign analogues.